Zimmer Biomet Holdings (ZBH) Securities Fraud Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet Holdings" or the "Company") (ZBH). Impacted investors are advised to contact the firm now.

What the Investigation Is About

The law firm is investigating whether Zimmer Biomet Holdings and certain of its officers or directors made false or misleading statements or failed to disclose material information about the Company’s financial performance, regional demand, and growth outlook between February 6, 2025, and November 4, 2025.

In early February 2025, Zimmer Biomet reported a 4.3% sales increase and reaffirmed its full-year outlook, describing the results as in line with expectations. In subsequent quarters, management emphasized steady progress, calling results “solid” and pointing to growth in its hip-replacement segment and new product launches. The Company also raised earnings guidance mid-year and continued to highlight product performance and demand trends across regions.

However, on November 5, 2025, Zimmer Biomet reported third-quarter revenue of roughly $2 billion, narrowly missing analyst expectations, and trimmed the upper end of its organic growth forecast from 4.5% to 4.0%. Executives attributed the change to slower sales in Latin America, Eastern Europe, and the Middle East, along with an unexpected $24 million to $25 million reduction tied to canceled distributor orders.

Market Reaction

Following these disclosures, the Company’s stock fell about 15%, dropping from $103.18 at close on November 4 to $87.55 on November 5, 2025, resulting in significant investor losses.

What Investors Can Do

If you purchased or otherwise acquired Zimmer Biomet Holdings (ZBH) securities between February 2025 and November 4, 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile, P.A. today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.